✓ Medically reviewed by · Last reviewed: May 2026
Pharmacy Researcher · 8 years experience
Pharmacy researcher with 8 years reviewing clinical drug information, generic formulation equivalence, and international pharmaceutical standards. Focuses on patient-facing accuracy in medication education.
Key takeaways
- Subcutaneous (SC) is the dominant route for most peptide research. Easiest technique, good bioavailability for most synthetic peptides, suitable for self-administration in research-protocol contexts.
- Intramuscular (IM) is preferred for larger volumes, recombinant proteins, and depot-style sustained-release research designs. Slower absorption profile than SC.
- Intranasal bypasses the blood-brain barrier via olfactory / trigeminal pathways — the right route for CNS-active peptides (Semax, Selank, DSIP, oxytocin in behavioural research).
- The choice of route changes the pharmacology, not just the convenience. Different absorption kinetics, different bioavailability, different tissue distribution.
- This guide covers the three routes and how to pick between them for any peptide research-protocol design.
Peptide Injection Routes: Subcutaneous vs Intramuscular vs Intranasal Compared
Most peptide research-protocols use one of three administration routes: subcutaneous (SC), intramuscular (IM), or intranasal. The choice isn’t arbitrary — each route produces different absorption kinetics, different bioavailability, and (importantly) different tissue distribution. This guide covers the three routes and the research scenarios that fit each.
Subcutaneous (SC): the default for most peptide research
SC injection delivers the peptide into the loose connective tissue beneath the skin (typically abdominal, thigh, or upper arm). Absorption is via local capillary uptake into systemic circulation. The route is preferred for most synthetic peptides because the technique is easy, the bioavailability is good for molecules under ~30 kDa, and the discomfort is minimal. Most molecule-specific research protocols on the catalogue (BPC-157, TB-500, CJC-1295, Ipamorelin, semaglutide, tirzepatide, retatrutide, etc.) use SC as the default.
Technique: insulin syringe with 29-31 gauge, 5/16 to 1/2 inch needle. Pinch a fold of skin, insert at 45-90 degrees depending on subject body composition, slowly inject, withdraw. Rotate sites to avoid lipohypertrophy from repeated injection at the same location.
Absorption profile: typically 30-60 minutes to peak plasma concentration for small synthetic peptides. The relatively slow absorption is part of why depot-style modifications (acylation for albumin binding, as in semaglutide, tirzepatide, retatrutide) are used to extend plasma residence further.
Intramuscular (IM): for larger volumes and depot-style research
IM injection delivers the peptide into the muscle belly (typically deltoid, vastus lateralis, or gluteus medius). The richer vascular supply in muscle tissue produces faster initial absorption than SC, but the volume capacity is larger (allowing administration of more concentrated or larger-volume preparations) and the depot effect is more pronounced.
Technique: longer needle (1 to 1.5 inch, 22-25 gauge for most peptide preparations), inserted perpendicular to the muscle, after aspirating to confirm not in a blood vessel. Site selection depends on the volume being administered.
When to pick IM over SC: larger volumes (over ~1 mL), recombinant proteins where the larger molecular weight reduces SC absorption efficiency (follistatin 344, GDF-8, HGH 191AA), depot-style research designs where slower release is the goal, and research-protocol scenarios where the institutional protocol specifies IM (e.g., HCG-class compounds where IM is the regulatory-precedent route).
Intranasal: the CNS-penetration route
Intranasal administration is mechanistically distinct from the two injection routes. Delivery via the nasal mucosa produces direct CNS exposure via two pathways: olfactory nerve transport (peptide travels along olfactory neurons from the nasal epithelium directly into the brain, bypassing the blood-brain barrier) and trigeminal nerve transport (similar direct CNS delivery via the trigeminal branches).
The CNS-penetration advantage is the defining feature. For peptides whose research endpoint is in the CNS — Semax (attention / BDNF), Selank (anxiolysis / GABA), DSIP (slow-wave sleep), oxytocin in behavioural-neuroscience research — intranasal delivery achieves meaningful CNS receptor exposure at doses that would produce minimal CNS exposure via SC or IM. Russian regulatory peptides (Semax, Selank) use intranasal as the registered finished-product route.
Technique: reconstituted solution delivered via intranasal spray applicator or dropper, typically 1-3 sprays per nostril per dose. The technique is more comfortable than injection and supports self-administration in research-protocol contexts.
Bioavailability caveat: intranasal bioavailability is variable and substantially lower than IV equivalent for the systemic compartment. The route is preferred for CNS endpoints, not for systemic-exposure protocols.
Comparison table
| Property | Subcutaneous (SC) | Intramuscular (IM) | Intranasal |
|---|---|---|---|
| Primary target | Systemic circulation | Systemic circulation (depot-style) | CNS (direct via olfactory / trigeminal) |
| Time to peak plasma | 30-60 min | 15-30 min (faster initial); longer tail | 5-15 min (CNS); lower systemic |
| Volume capacity | Up to 1 mL practical | Up to 3-5 mL | ~100-200 mcL per nostril |
| Needle size | 29-31g, 5/16-1/2 in | 22-25g, 1-1.5 in | No needle (spray) |
| Best for | Most synthetic peptides, daily dosing | Recombinant proteins, larger volumes, depot | CNS-active peptides |
| Example peptides | BPC-157, CJC-1295, Ipamorelin, GLP-1 class | Follistatin 344, HGH 191AA, HCG | Semax, Selank, DSIP, oxytocin (behavioural) |
Which route for which peptide
Tissue-repair cluster (BPC-157, TB-500, KPV, GHK-Cu, AHK-Cu) — SC is the default. Topical is also published for the copper peptides specifically.
GH-axis cluster (Sermorelin, CJC-1295, Tesamorelin, Ipamorelin, GHRP-2/6) — SC. HGH 191AA can use either SC or IM depending on the dose volume and protocol.
GLP-1 / metabolic cluster (semaglutide, tirzepatide, retatrutide, etc.) — SC. The route follows the FDA-approved comparator-drug labelling.
CNS / nootropic cluster (Semax, Selank, DSIP, Adamax) — intranasal for the CNS endpoint; SC is also published for systemic-mechanism research.
Longevity cluster (Epitalon, NAD⁺, SS-31, MOTS-c) — SC primary. NAD⁺ specifically uses IV for high-bioavailability protocols.
Sexual / reproductive (PT-141, oxytocin, kisspeptin-10) — PT-141 SC; oxytocin intranasal for behavioural research, IM/IV for obstetric-comparator protocols; kisspeptin-10 SC or short IV bolus.
Muscle / myostatin (follistatin 344, GDF-8) — IM preferred for recombinant proteins of this size.
Research-use disclaimer
All routes described are for laboratory research use of peptide compounds. The peptides on the catalogue are sold for in-vitro research and analytical reference use only. None of this constitutes medical advice for human therapeutic administration.
FAQ
Why does the route affect the pharmacology and not just the convenience?
Because different routes produce different absorption kinetics, different bioavailability, and different tissue distribution. SC produces moderate-speed systemic exposure. IM produces faster initial absorption with a longer depot tail. Intranasal bypasses the blood-brain barrier via olfactory and trigeminal nerves, producing direct CNS exposure at far lower systemic doses than injection routes would achieve.
Can I always substitute SC for IM?
No. For recombinant proteins of larger molecular weight (follistatin 344, GDF-8, HGH 191AA), SC absorption is less efficient than IM. For HCG-class compounds where IM is the regulatory-precedent route, SC may produce lower bioavailability than the published comparator-drug protocols. Check the specific molecule’s published route before substituting.
Does intranasal work for systemic-exposure research?
Not optimally. Intranasal bioavailability for systemic exposure is variable and substantially lower than IV equivalent. The route is preferred for CNS endpoints (where the direct olfactory/trigeminal pathway is the design point), not for systemic-exposure protocols where consistent peripheral plasma levels are the goal.
What needle size for SC peptide injection?
29-31 gauge, 5/16 to 1/2 inch length on a 1 mL / 100 IU insulin syringe. The fine gauge minimises discomfort and is sufficient for the low-volume injections typical of peptide research-protocol doses.
Can peptides be administered orally?
Mostly not. Most peptides are degraded by gastric proteases before reaching systemic circulation, which is why injection / intranasal routes dominate. Exceptions include BPC-157 (unusual oral bioavailability attributed to structural stability), KPV (small tripeptide), and a few others. For most molecules on the catalogue, oral administration is not a practical research route.
What about topical for cosmetic peptides?
Yes — topical is a valid and well-published route for the cosmetic-research cluster specifically (GHK-Cu, AHK-Cu). The copper peptides are stratum-corneum-permeable in topical-formulation research at typical cosmetic-research concentrations. See: Best cosmetic peptides.
Bottom line
SC is the default route for most peptide research-protocol designs. IM is preferred for recombinant proteins, larger volumes, and depot-style sustained-release research. Intranasal is the CNS-penetration route for nootropic / CNS-active peptides where the olfactory and trigeminal pathways bypass the blood-brain barrier. The route selection is part of the research-protocol design, not a convenience choice — different routes produce different pharmacology.
Related research guides
Written by
Sophie ChenPharmaceutical Content Researcher · 8 years experience
Sophie Chen is a pharmaceutical content researcher with 8 years covering generic medication access and clinical pharmacology. She specialises in international regulatory frameworks, bioequivalence standards, and patient-facing education on therapeutic drug classes. She is not a clinician.